Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 2
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Odelepran"
Page 1
Opioid modulators for alcohol dependence.
Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H. Hillemacher T, et al. Expert Opin Investig Drugs. 2011 Aug;20(8):1073-86. doi: 10.1517/13543784.2011.592139. Epub 2011 Jun 9. Expert Opin Investig Drugs. 2011. PMID: 21651459 Review.
Naltrexone- and to a lesser extent nalmefene- is an agent that modulates opioidergic transmission in the CNS and it shows a limited but well-studied efficacy in treating alcohol dependence. Several agents (LY2196044, ALKS-29, ALKS-33) that are currently undergoing Phase II …
Naltrexone- and to a lesser extent nalmefene- is an agent that modulates opioidergic transmission in the CNS and it shows a limited but well …
Investigation of clinical pharmacokinetic variability of an opioid antagonist through physiologically based absorption modeling.
Ding X, He M, Kulkarni R, Patel N, Zhang X. Ding X, et al. J Pharm Sci. 2013 Aug;102(8):2859-74. doi: 10.1002/jps.23629. Epub 2013 Jun 11. J Pharm Sci. 2013. PMID: 23761048 Clinical Trial.
Here we present an integrated approach of physiologically based absorption modeling to investigate the root cause of unexpectedly high PK variability of a Phase I clinical trial drug. LY2196044 exhibited high intersubject variability in the absorption phase of plasma conce …
Here we present an integrated approach of physiologically based absorption modeling to investigate the root cause of unexpectedly high PK va …
A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.
Wong CJ, Witcher J, Mallinckrodt C, Dean RA, Anton RF, Chen Y, Fijal BA, Ouyang H, Dharia S, Sundseth SS, Schuh KJ, Kinon BJ. Wong CJ, et al. Alcohol Clin Exp Res. 2014 Feb;38(2):511-20. doi: 10.1111/acer.12257. Epub 2013 Sep 6. Alcohol Clin Exp Res. 2014. PMID: 24010675 Clinical Trial.
RESULTS: The treatment difference in change from baseline in % HDD between LY2196044 and placebo was not statistically significant (-43.02 vs. -38.72%, respectively; p = 0.12). ...The safety profile for LY2196044 appeared similar to that of other opioid antagonists. …
RESULTS: The treatment difference in change from baseline in % HDD between LY2196044 and placebo was not statistically significant (- …